Condition: Multiple Myeloma · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
This description comes directly from the study's public registry record.
Peng Liu, Doctor · 021-60267405 · Liu.peng@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The Affiliated Hospital of Chengde Medical College | Chengde, Hebei, China | Not Yet Recruiting |
| North China University of Science and Technology Affiliated Hospital | Tangshan, Hebei, China | Not Yet Recruiting |
| Nanjing Drum Tower hospital | Nanjing, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| Nanchang University First Affiliated Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an, Shaanxi, China | Recruiting |
| Heze Municipal Hospital | Heze, Shandong, China | Not Yet Recruiting |
| Zhongshan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07179679